Free Trial
NASDAQ:LXEO

Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Lexeo Therapeutics logo
$3.94 -0.02 (-0.38%)
As of 10:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Lexeo Therapeutics Stock (NASDAQ:LXEO)

Key Stats

Today's Range
$3.86
$3.96
50-Day Range
$2.63
$4.61
52-Week Range
$1.45
$13.63
Volume
60,272 shs
Average Volume
529,235 shs
Market Capitalization
$130.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Buy

Company Overview

Lexeo Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

LXEO MarketRank™: 

Lexeo Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 724th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lexeo Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Lexeo Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lexeo Therapeutics are expected to grow in the coming year, from ($3.14) to ($2.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexeo Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexeo Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexeo Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Lexeo Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    22.49% of the float of Lexeo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexeo Therapeutics has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Lexeo Therapeutics has recently increased by 7.74%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lexeo Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lexeo Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.49% of the float of Lexeo Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lexeo Therapeutics has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Lexeo Therapeutics has recently increased by 7.74%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lexeo Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for LXEO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,612.00 in company stock.

  • Percentage Held by Insiders

    Only 5.30% of the stock of Lexeo Therapeutics is held by insiders.

  • Percentage Held by Institutions

    60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lexeo Therapeutics' insider trading history.
Receive LXEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LXEO Stock News Headlines

Bitcoin Beats Gold — But This Coin Could Beat Them Both
Bitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, who called Bitcoin’s breakout to $100K nearly to the day, says a lesser-known coin could be even bigger. It’s faster, cheaper, and backed by Google, Visa, and top VCs with over $200 million already invested.
Why Lexeo Is Rising In Pre-market? - Nasdaq
See More Headlines

LXEO Stock Analysis - Frequently Asked Questions

Lexeo Therapeutics' stock was trading at $6.58 at the start of the year. Since then, LXEO stock has decreased by 39.8% and is now trading at $3.96.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.19.

Lexeo Therapeutics (LXEO) raised $100 million in an initial public offering (IPO) on Friday, November 3rd 2023. The company issued 9,090,910 shares at $11.00 per share.

Lexeo Therapeutics' top institutional investors include Palumbo Wealth Management LLC (0.17%). Insiders that own company stock include Fund Vi LP Omega, Richard Nolan Townsend, Eric Adler and Tai Sandi See.
View institutional ownership trends
.

Shares of LXEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexeo Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
5/12/2025
Today
7/21/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LXEO
Previous Symbol
NASDAQ:LXEO
CIK
1907108
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$10.00
Potential Upside/Downside
+319.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$98.33 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-85.86%
Return on Assets
-68.48%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
3.42
Quick Ratio
3.42

Sales & Book Value

Annual Sales
$650 thousand
Price / Sales
202.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.53 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
33,200,000
Free Float
31,438,000
Market Cap
$131.47 million
Optionable
Not Optionable
Beta
1.32
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:LXEO) was last updated on 7/22/2025 by MarketBeat.com Staff
From Our Partners